Literature DB >> 20651937

Monofunctionalization of Calix[4]arene Tetracarboxylic Acid at the Upper Rim with Isothiocyanate Group: First Bifunctional Chelating Agent for Alpha-Emitter Ac-225.

Xiaoyuan Chen1, Min Ji, Darrell R Fisher, Chien M Wai.   

Abstract

A procedure is reported for synthesizing a novel, water-soluble bifunctional chelating agent derived from calix[4]arene. This chelate features tetracarboxylic acid groups at the lower rim as an actinium-225 ionophore, and an isothiocyanate functional group at the upper rim for labeling of the N-terminus of monoclonal antibodies through thiourea linkage.

Entities:  

Year:  1999        PMID: 20651937      PMCID: PMC2907548          DOI: 10.1055/s-1999-2944

Source DB:  PubMed          Journal:  Synlett        ISSN: 0936-5214            Impact factor:   2.454


  4 in total

1.  The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy.

Authors:  M W Geerlings; F M Kaspersen; C Apostolidis; R van der Hout
Journal:  Nucl Med Commun       Date:  1993-02       Impact factor: 1.690

2.  Water-Soluble Neutral Calix[4]arene-Lanthanide Complexes: Synthesis and Luminescence Properties.

Authors:  Frank J. Steemers; Hans G. Meuris; Willem Verboom; David N. Reinhoudt; Erik B. van Der Tol; Jan W. Verhoeven
Journal:  J Org Chem       Date:  1997-06-27       Impact factor: 4.354

3.  Radioimmunotherapy with alpha-particle-emitting immunoconjugates.

Authors:  R M Macklis; B M Kinsey; A I Kassis; J L Ferrara; R W Atcher; J J Hines; C N Coleman; S J Adelstein; S J Burakoff
Journal:  Science       Date:  1988-05-20       Impact factor: 47.728

4.  Syntheses and properties of luminescent lanthanide chelate labels and labeled haptenic antigens for homogeneous immunoassays.

Authors:  H Mikola; H Takalo; I Hemmilä
Journal:  Bioconjug Chem       Date:  1995 May-Jun       Impact factor: 4.774

  4 in total
  1 in total

1.  Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.

Authors:  Nikki A Thiele; Justin J Wilson
Journal:  Cancer Biother Radiopharm       Date:  2018-06-11       Impact factor: 3.099

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.